We serve Chemical Name:4,5-Dichloro-6-nitropyridazin-3-ol CAS:13645-43-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:4,5-Dichloro-6-nitropyridazin-3-ol
CAS.NO:13645-43-7
Synonyms:4,5-Dichloro-6-nitropyridazin-3-ol;4,5-dichloro-6-nitro-2H-pyridazin-3-one;4,5-dichloro-6-nitro-2,3-dihydropyridazin-3-one;4,5-dichloro-6-nitro-3(2H)pyridazinone
Molecular Formula:C4HCl2N3O3
Molecular Weight:209.97500
HS Code:2933990090
Physical and Chemical Properties:
Melting point:184ºC
Boiling point:N/A
Density:2.11 g/cm3
Index of Refraction:
PSA:91.83000
Exact Mass:208.93900
LogP:1.92040
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 4,5-Dichloro-6-nitropyridazin-3-ol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4,5-dichloro-6-nitro-3(2H)pyridazinone physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4,5-Dichloro-6-nitropyridazin-3-ol Use and application,4,5-Dichloro-6-nitropyridazin-3-ol technical grade,usp/ep/jp grade.
Related News: In a statement to Fierce Medtech, Innova said it has completed some corrective actions, while others are still underway, and that the U.S. recall was launched to reclaim tests distributed to employees, clinical studies and to customers for early evaluation. The company said it plans to seek an emergency use authorization and comply with all FDA requirements. 4,5-Dichloro-6-nitropyridazin-3-ol manufacturer The purpose of APIs according to the FDA is to cause ��pharmacological activity or other direct effects in the diagnosis, cure, mitigation, treatment or prevention of disease or to affect the structure and function of the human body. 4,5-Dichloro-6-nitropyridazin-3-ol supplier I’ve had successful major surgery to remove it, and I’m now undergoing several months of chemotherapy for the very best possible long-term prognosis, and I’m confident,” she said Monday at the beginning of her daily television program, CNN reported.
Amanpour, 63, has been off work for the past four weeks due to her condition. As she undergoes chemotherapy, she expects to anchor Mondays through Wednesdays. She also has three weeks of previously booked time off that starts at the end of June.
Amanpour noted that ovarian cancer is all too common, affecting “millions of women around the world. 4,5-Dichloro-6-nitropyridazin-3-ol vendor The downstream industry of the pharmaceutical intermediate industry is mainly the production of APIs, and the relationship between APIs and preparations is in the upstream and downstream industry chain. The consumer demand for downstream preparations will directly affect the demand for APIs. 4,5-Dichloro-6-nitropyridazin-3-ol factory In a statement to Fierce Medtech, Innova said it has completed some corrective actions, while others are still underway, and that the U.S. recall was launched to reclaim tests distributed to employees, clinical studies and to customers for early evaluation. The company said it plans to seek an emergency use authorization and comply with all FDA requirements.
Amanpour, 63, has been off work for the past four weeks due to her condition. As she undergoes chemotherapy, she expects to anchor Mondays through Wednesdays. She also has three weeks of previously booked time off that starts at the end of June.
Amanpour noted that ovarian cancer is all too common, affecting “millions of women around the world. 4,5-Dichloro-6-nitropyridazin-3-ol vendor The downstream industry of the pharmaceutical intermediate industry is mainly the production of APIs, and the relationship between APIs and preparations is in the upstream and downstream industry chain. The consumer demand for downstream preparations will directly affect the demand for APIs. 4,5-Dichloro-6-nitropyridazin-3-ol factory In a statement to Fierce Medtech, Innova said it has completed some corrective actions, while others are still underway, and that the U.S. recall was launched to reclaim tests distributed to employees, clinical studies and to customers for early evaluation. The company said it plans to seek an emergency use authorization and comply with all FDA requirements.
